Tissue Repository Core

摘要-儿科流变学组织库（PRTR） 强大而严格的生物标本采集基础设施对于加速创新转化至关重要 儿科风湿病学的研究项目。儿科流变学组织库（PRTR） 成立于1996年，并一直得到NIAMS资金的支持，以最大限度地提高样本的价值。 翻译研究的收藏。自2017年以来，PRTR一直担任美国儿童生物库 关节炎流变学研究联盟（CARRA）研究登记处，最大的儿科纵向研究 北美的风湿性疾病拟议的污染物排放和转移登记簿的总体目标是加速转型， 通过促进获得有价值的高质量生物标本， 创新的翻译研究项目。为实现这一目标，提出了以下目标。上 PRTR将收集、处理和保存来自儿科患者的高质量生物标本。 风湿病和相关的肌肉骨骼疾病，以支持和发展当地的研究社区。这 包括促进专门针对研究者的大规模样本采集的设计和管理， 开始了翻译研究。这也包括正在进行的高价值生物标本（新发 疾病和剩余的液体和组织），并支持早期研究者进行试点生物样本收集 有创新的研究方向，但缺乏实验室基础设施。在目标2中，污染物排放和转移登记册将扩大 全国小儿风湿病研究生物标本采集范围。污染物排放和转移登记册将支持 开发和实施适用于新兴基因组研究的先进生物标本收集 方法，特别是从非血液组织，包括超声引导的滑膜和肾活检，骨 骨髓、支气管肺泡灌洗（BAL）和肺组织。与此同时，污染物排放和转移登记册与 CARRA将用于支持方案制定、研究设计协助、研究中心培训和 在各个CARRA注册中心进行高级处理的基础设施开发。最后，在目标3中， 污染物排放和转移登记册将优化生物样本收集的提供、获取和使用。这包括近实时，等分- 水平，去识别样本数据，以验证，并完全集成的表型和生物库信息 将继续通过RheumsMart（PRTR的安全在线数据集市）进行搜索。我们还将升级 从本地和CARRA采集的生物库跟踪系统到行业领先的LabVantage LIMS。采取 总之，污染物排放和转移登记册将为生物标本收集提供一个集中的、高质量的、宝贵的资源， 处理和存储，以支持CCHMC和全国的研究社区。这些资源将 加快转化研究计划，以进一步实现CRDRC的总体目标， 了解小儿风湿性疾病，并导致这些疾病的新疗法。

Abstract – Pediatric Rheumatology Tissue Repository (PRTR) A robust and rigorous infrastructure for biospecimen collection is essential for accelerate innovative translational research projects in pediatric rheumatology. The Pediatric Rheumatology Tissue Repository (PRTR) was established in 1996 and has been continuously supported by NIAMS funding to maximize the value of sample collections for translational research. Since 2017, the PRTR has served as the US biobank for the Childhood Arthritis Rheumatology Research Alliance (CARRA) Research Registry, the largest longitudinal study of pediatric rheumatic diseases in North America. The overall objective of the proposed PRTR is to accelerate transformative discovery in pediatric rheumatology by facilitating access to valuable and high quality biospecimens for innovative translational research projects. The following aims are proposed to achieve this objective. In the first aim, the PRTR will collect, process and maintain high quality biological specimens from patients with pediatric rheumatologic and related musculoskeletal conditions to support and grow the local research community. This includes facilitating the design and management of large-scale sample collections specific to investigator- initiated translational research. This also includes ongoing collection of high value biospecimens (new-onset disease and leftover fluid and tissue), and support for pilot biosample collections by early-stage investigators with innovative research directions but who lack laboratory infrastructure. In Aim 2, the PRTR will expand the scope of biospecimen collection for pediatric rheumatic disease research nationally. The PRTR will support development and implementation of advanced biospecimen collections suitable for emerging genomic approaches, particularly from non-blood tissues including ultrasound-guided synovial and kidney biopsy, bone marrow, bronchoalveolar lavage (BAL), and lung tissue. In parallel, the partnership between the PRTR and CARRA will be leveraged to support protocol development, study design assistance, site training, and infrastructure development for advanced processing at individual CARRA Registry sites. Finally in Aim 3, the PRTR will optimize availability, access to and use of biosample collections. This includes near-real-time, aliquot- level, de-identified specimen data to authenticated, and fully integrated phenotypic and biobanking information will continue to be searchable through RheumsMart, the PRTR’s secure online data mart. We will also upgrade biobanking tracking system for both local and CARRA collections to industry-leading LabVantage LIMS. Taken together, the PRTR will provide a centralized, high quality, valuable resource for biospecimen collection, processing, and storage to support the Research Community at CCHMC and nationally. These resources will accelerate translational research initiatives to further the overall goal of the CRDRC to advance the understanding of pediatric rheumatic diseases and lead to new therapies for these diseases.